Full Episode
US$ 21.51
surmount-1 trial tirzepatide weight loss non-diabetic reduction with different doses of in Surmount 1 SURMOUNT-1 Trial - Cardionerds Twitter
Description
IntroductionOral semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved for the treatment of type 2 diabetes mellitus (T2DM)
Proper storage is essential to preserve medication strength and ensure treatment effectiveness
Antiamyloid therapies have recently changed the treatment landscape
A study in Nature found a specific genetic variant that may boost the effectiveness of GLP-1 weight-loss drugs like semaglutide and tirzepatide.
Tirzepatide (Mounjaro) is a dual-action medication for type 2 diabetes and obesity, offering blood sugar control and weight loss, with potential side effects.
